Impact of prior systemic corticosteroid use in patients admitted with community-acquired pneumonia

Adriel Malave, Elena Laserna, Oriol Sibila, Eric M. Mortensen, Antonio R Anzueto, Marcos Restrepo

Research output: Contribution to journalArticle

1 Citation (Scopus)

Abstract

Background and objective: Limited information is available regarding the impact of prior outpatient use of systemic corticosteroids (SCS) in patients subsequently developing community-acquired pneumonia (CAP). We investigate the effects of prior SCS on severity of illness, microbiology and clinical outcomes for patients hospitalized with CAP. Methods: A retrospective cohort study of subjects with CAP (according to International Classification of Diseases, 9th edition codes) was conducted over a 3-year period at two tertiary teaching hospitals. Subjects were considered to be SCS users if they received oral corticosteroids prior to admission. Primary outcomes were severity of illness, microbiology and 30-day mortality. Results: Data were abstracted on 698 patients [prior SCS users, 75 (10.7%) versus prior non-SCS users 623 (89.3%)]. Prior SCS users were more likely to have chronic obstructive pulmonary disease. No differences were found in severity of disease at admission, microbiological etiology including opportunistic and drug-resistant pathogens and clinical outcomes, including 30-day mortality, intensive care unit admission, length of hospital stay, need for mechanical ventilation and need for vasopressors. Conclusion: Prior SCS use is not associated with increased 30-day mortality for patients hospitalized with CAP. In addition, no differences were found in either the severity of the disease at the time of presentation or in the presence of the resistant or opportunistic pathogens among groups.

Original languageEnglish (US)
Pages (from-to)323-330
Number of pages8
JournalTherapeutic Advances in Respiratory Disease
Volume6
Issue number6
DOIs
StatePublished - Dec 2012

Fingerprint

Pneumonia
Adrenal Cortex Hormones
Microbiology
Mortality
Length of Stay
International Classification of Diseases
Artificial Respiration
Tertiary Care Centers
Teaching Hospitals
Chronic Obstructive Pulmonary Disease
Intensive Care Units
Cohort Studies
Outpatients
Retrospective Studies
Pharmaceutical Preparations

Keywords

  • corticosteroids
  • drug resistance
  • microbial
  • mortality
  • pneumonia
  • severity of illness index

ASJC Scopus subject areas

  • Pulmonary and Respiratory Medicine
  • Pharmacology (medical)

Cite this

Impact of prior systemic corticosteroid use in patients admitted with community-acquired pneumonia. / Malave, Adriel; Laserna, Elena; Sibila, Oriol; Mortensen, Eric M.; Anzueto, Antonio R; Restrepo, Marcos.

In: Therapeutic Advances in Respiratory Disease, Vol. 6, No. 6, 12.2012, p. 323-330.

Research output: Contribution to journalArticle

@article{79740604edab49a28b6a01df408580fd,
title = "Impact of prior systemic corticosteroid use in patients admitted with community-acquired pneumonia",
abstract = "Background and objective: Limited information is available regarding the impact of prior outpatient use of systemic corticosteroids (SCS) in patients subsequently developing community-acquired pneumonia (CAP). We investigate the effects of prior SCS on severity of illness, microbiology and clinical outcomes for patients hospitalized with CAP. Methods: A retrospective cohort study of subjects with CAP (according to International Classification of Diseases, 9th edition codes) was conducted over a 3-year period at two tertiary teaching hospitals. Subjects were considered to be SCS users if they received oral corticosteroids prior to admission. Primary outcomes were severity of illness, microbiology and 30-day mortality. Results: Data were abstracted on 698 patients [prior SCS users, 75 (10.7{\%}) versus prior non-SCS users 623 (89.3{\%})]. Prior SCS users were more likely to have chronic obstructive pulmonary disease. No differences were found in severity of disease at admission, microbiological etiology including opportunistic and drug-resistant pathogens and clinical outcomes, including 30-day mortality, intensive care unit admission, length of hospital stay, need for mechanical ventilation and need for vasopressors. Conclusion: Prior SCS use is not associated with increased 30-day mortality for patients hospitalized with CAP. In addition, no differences were found in either the severity of the disease at the time of presentation or in the presence of the resistant or opportunistic pathogens among groups.",
keywords = "corticosteroids, drug resistance, microbial, mortality, pneumonia, severity of illness index",
author = "Adriel Malave and Elena Laserna and Oriol Sibila and Mortensen, {Eric M.} and Anzueto, {Antonio R} and Marcos Restrepo",
year = "2012",
month = "12",
doi = "10.1177/1753465812458985",
language = "English (US)",
volume = "6",
pages = "323--330",
journal = "Therapeutic Advances in Respiratory Disease",
issn = "1753-4658",
publisher = "SAGE Publications Ltd",
number = "6",

}

TY - JOUR

T1 - Impact of prior systemic corticosteroid use in patients admitted with community-acquired pneumonia

AU - Malave, Adriel

AU - Laserna, Elena

AU - Sibila, Oriol

AU - Mortensen, Eric M.

AU - Anzueto, Antonio R

AU - Restrepo, Marcos

PY - 2012/12

Y1 - 2012/12

N2 - Background and objective: Limited information is available regarding the impact of prior outpatient use of systemic corticosteroids (SCS) in patients subsequently developing community-acquired pneumonia (CAP). We investigate the effects of prior SCS on severity of illness, microbiology and clinical outcomes for patients hospitalized with CAP. Methods: A retrospective cohort study of subjects with CAP (according to International Classification of Diseases, 9th edition codes) was conducted over a 3-year period at two tertiary teaching hospitals. Subjects were considered to be SCS users if they received oral corticosteroids prior to admission. Primary outcomes were severity of illness, microbiology and 30-day mortality. Results: Data were abstracted on 698 patients [prior SCS users, 75 (10.7%) versus prior non-SCS users 623 (89.3%)]. Prior SCS users were more likely to have chronic obstructive pulmonary disease. No differences were found in severity of disease at admission, microbiological etiology including opportunistic and drug-resistant pathogens and clinical outcomes, including 30-day mortality, intensive care unit admission, length of hospital stay, need for mechanical ventilation and need for vasopressors. Conclusion: Prior SCS use is not associated with increased 30-day mortality for patients hospitalized with CAP. In addition, no differences were found in either the severity of the disease at the time of presentation or in the presence of the resistant or opportunistic pathogens among groups.

AB - Background and objective: Limited information is available regarding the impact of prior outpatient use of systemic corticosteroids (SCS) in patients subsequently developing community-acquired pneumonia (CAP). We investigate the effects of prior SCS on severity of illness, microbiology and clinical outcomes for patients hospitalized with CAP. Methods: A retrospective cohort study of subjects with CAP (according to International Classification of Diseases, 9th edition codes) was conducted over a 3-year period at two tertiary teaching hospitals. Subjects were considered to be SCS users if they received oral corticosteroids prior to admission. Primary outcomes were severity of illness, microbiology and 30-day mortality. Results: Data were abstracted on 698 patients [prior SCS users, 75 (10.7%) versus prior non-SCS users 623 (89.3%)]. Prior SCS users were more likely to have chronic obstructive pulmonary disease. No differences were found in severity of disease at admission, microbiological etiology including opportunistic and drug-resistant pathogens and clinical outcomes, including 30-day mortality, intensive care unit admission, length of hospital stay, need for mechanical ventilation and need for vasopressors. Conclusion: Prior SCS use is not associated with increased 30-day mortality for patients hospitalized with CAP. In addition, no differences were found in either the severity of the disease at the time of presentation or in the presence of the resistant or opportunistic pathogens among groups.

KW - corticosteroids

KW - drug resistance

KW - microbial

KW - mortality

KW - pneumonia

KW - severity of illness index

UR - http://www.scopus.com/inward/record.url?scp=84870192191&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84870192191&partnerID=8YFLogxK

U2 - 10.1177/1753465812458985

DO - 10.1177/1753465812458985

M3 - Article

VL - 6

SP - 323

EP - 330

JO - Therapeutic Advances in Respiratory Disease

JF - Therapeutic Advances in Respiratory Disease

SN - 1753-4658

IS - 6

ER -